Experimental cell therapy targets tough autoimmune diseases
NCT ID NCT07212322
Summary
This early-stage study is testing a new cell therapy called CD19 UCAR-T in people with severe autoimmune diseases that haven't improved with standard treatments. Researchers will modify a patient's own immune cells to target and remove certain B cells thought to drive these diseases. The main goals are to see if the treatment is safe and if it can help control the diseases in 24 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.